Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine

Reichmann, U.; Bokemeyer, Carsten; Wallwiener, D.; Bamberg, M.; Huober, Jens

doi:10.1093/annonc/mdm378

Cited by 22 publications

(19 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An American group in Ohio currently investigates the combination of bendamustine with erlotinib [16]. We found a median PFS of 7.3 months (95% CI: 5.5-10.9), which is significantly higher in comparison with the PFS in the studies of Steinbild et al [7] and Reichmann et al [4] (median time to progression (TTP) 4.2 months and 3.4 months, respectively). The median OS was 14.9 months in the RiTa study (95% CI: 9.9-22.9), compared to a median OS of 11.3 months with bendamustine monotherapy [7].…”

Section: Efficacy Resultsmentioning

confidence: 66%

“…Whereas with bendamustine monotherapy no complete remission was reported. However, the patients in the other studies were heavily pretreated (with 66.7% having received 2 or more previous regimens) [4]. The collective in our study has received up to 1 chemotherapy regimen in the metastatic situation; therefore, the results are not exactly comparable and inter-trial comparisons have to be done with caution.…”

Section: Efficacy Resultsmentioning

confidence: 70%

“…The median OS was 14.9 months in the RiTa study (95% CI: 9.9-22.9), compared to a median OS of 11.3 months with bendamustine monotherapy [7]. In the phase II study of Reichmann et al [4], bendamustine as single agent was applied at a dose of 120 mg/m 2 on days 1 + 2 every 4 weeks. A partial response was described in 20% and stable disease for at least 6 months in 28% of the patients.…”

Section: Efficacy Resultsmentioning

confidence: 99%

“…It combines a bifunctional alkylating nitrogen mustard derivative and a purine-like benzimidazol and induces more long-lasting DNA double-strand breaks compared to other alkylating agents [1,2]. So far, bendamustine has been used in metastatic breast cancer either as monotherapy or in combination with methotrexate/5-fluorouracil as substitute for cyclophosphamide or an anthracycline or vincristine with moderate activity [3][4][5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial

Loibl

Doering²,

Müller³

et al. 2011

Breast Care

View full text Add to dashboard Cite

The combination of bendamustine (B) and paclitaxel (P) as anthracycline-free treatment option in patients with advanced breast cancer has been evaluated in the previous RiTa I trial. The regimen of weekly B 70 mg/m² and P 90 mg/m² with a pause every 4th week was established as an effective regimen with low toxicity. The aim of the present RiTa II study was to investigate the potential of BP as anthracycline-free combination therapy. The primary objective was to determine the progression-free survival (PFS); secondary endpoints were safety, tolerability, overall response rate (ORR) and overall survival (OS). 26 patients were available, 15 received BP as first-line, 11 as beyond first-line treatment. 27% patients had triple-negative breast cancer (TNBC). Median PFS and OS were 7.3 months (95% confidence interval (CI): 5.5–10.9) and 14.9 months (95% CI: 9.9–22.9), respectively. The 1-year PFS rate was 20.3% and the 1-year OS rate 71.2%. The ORR was 42.3%, including 4 complete and 7 partial remissions. TNBC patients reached an ORR of 71.4%. Anthracycline-pretreated patients showed an ORR of 43.8%, confirming bendamustine’s lack of crossresistance to anthracycline agents. BP represents a favorable option with moderate toxicity in pretreated metastatic breast cancer and offers a possibility for application in anthracycline-pretreated and TNBC patients.

show abstract

Section: Efficacy Resultsmentioning

confidence: 66%

Section: Efficacy Resultsmentioning

confidence: 70%

Section: Efficacy Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial

Loibl

Doering²,

Müller³

et al. 2011

Breast Care

View full text Add to dashboard Cite

show abstract

“…A multicenter, open-label, nonrandomized phase II trial has investigated the efficacy and tolerability of single-agent bendamustine in 51 multimodally pretreated patients, with a dose of 120 mg/m 2 on days 1 and 2 every 4 weeks [25]. Most patients (92%) had received chemotherapy for metastatic disease, 53% adjuvant chemotherapy, and 47% an adjuvant hormone therapy.…”

Section: Bendamustine As Monotherapy In Mbcmentioning

confidence: 99%

Bendamustine in Metastatic Breast Cancer: An Old Drug in New Design

Pîrvulescu¹,

Minckwitz²,

Loibl³

2008

Breast Care

View full text Add to dashboard Cite

The goal of treatment for patients with advanced breast cancer is to prolong survival, control symptoms, and reduce disease-related complications. Despite the introduction of many cytotoxic agents during the past decade, only modest improvement in survival in metastatic breast cancer has been achieved. In order to improve this situation, new cytotoxic drugs as well as molecule-targeted agents are now under investigation. Bendamustine is a bifunctional alkylating agent with cytotoxic activity against several types of solid tumors. In the search for new anthracycline-free combinations, taxanes and alkylating agents might be worth investigating, in order to reduce cardiac toxicity. In this article, we reviewed the latest information regarding antitumor activity, toxicity, pharmacokinetics, and clinical application of bendamustine as a cytotoxic agent in metastatic breast cancer.

show abstract

A Supramolecular Nanomedicine Based on Bendamustine and MDM2‐Targeted D‐peptide Inhibitor for Breast Cancer Therapy

Zhou

Chen

Huang

et al. 2021

Adv Healthcare Materials

View full text Add to dashboard Cite

Bendamustine (BEN) is a FDA-approved bifunctional DNA-alkylating chemotherapy drug, but it suffers from short half-life, instability, and poor biocompatibility in the clinical application. Due to unique biostability of d-amino acid-containing peptides (D-peptides), constructing D-peptide-small molecule drug conjugates is emerging as a promising strategy for cancer therapy. Here, a high-affinity MDM2-targeted D-peptide (peptide 5) is discovered by applying structure-based drug design (SBDD). Taking the advantages of d-amino acids, a novel self-assembling D-peptide-small molecule drug conjugate (BEN-FF-peptide 5) is developed by simultaneously conjugating small molecule drug BEN and peptide 5 to the self-assembling peptide. In vitro results demonstrate that BEN-FF-peptide 5 exhibits superior cellular uptake ability, good biostability in human serum and strong inhibitory effect on the growth of human breast cancer (MCF-7) cells. In vivo study reveals that BEN-FF-peptide 5 significantly inhibits the growth of MCF-7 cells-derived xenograft in nude mice with no obvious side effects. This work provides a useful strategy to construct D-peptide-small molecule drug conjugates for high-efficacy and low-toxicity cancer therapy.

show abstract

Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine

Abstract: Single-agent bendamustine is an active treatment in patients with MBC independent of the previous treatment. The low toxicity profile favors its use as a single agent.

Cited by 22 publications

References 7 publications

Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial

Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial

Bendamustine in Metastatic Breast Cancer: An Old Drug in New Design

A Supramolecular Nanomedicine Based on Bendamustine and MDM2‐Targeted D‐peptide Inhibitor for Breast Cancer Therapy

Contact Info

Product

Resources

About